Our process is transparent and reproducible, making biological interpretation possible.
Our AI Lab is led by Top 100 AI Leader and Chief Data Science Officer, Tom Chittenden, PhD, DPhil, PStat. The AI Team apply our proprietary, domain-specific Artificial Intelligence (AI) algorithms to reveal novel patterns and causal dependencies to advance biological understanding.
Our approach uncovers new and actionable insights from the exponentially growing pool of genomic and phenotypic data in precision medicine. Our capabilities speed genomic research as well as drug discovery, design, and development, including optimal clinical trial design.
We provide leading-edge data analysis to:
Here we show that endothelial transforming growh factor β (TGF-β) signalling is one of the primary drivers of atherosclerosis-associated vascular inflammation. Inhibition of endothelial TGF-β signalling in hyperlipidemic mice reduces vessel wall inflammation and vascular permeability and leads to arrest of disease progression and regression of established lesions.Learn more
Several advances in A.I. are making a transformative impact on drug R&D—changing the landscape and making it possible to finally uncover the molecular underpinnings and complex pathways of diseases that have long remained mysteries.Learn More
Tom Chittenden, head of WuXi NextCODE’s AI team, was recently named one of the “Top 100 AI Leaders in Drug Discovery and Advanced Healthcare.” Analysts at Deep Knowledge Analytics drew up the list from a pool of several hundred renowned scientists.Learn More
Latest cardiovascular disease breakthrough in partnership with Yale single-cell biology team provides validated starting point for the development of new therapeutics and disease prevention strategiesLearn More